DalsnaFinance

STARMED Becomes First Company to Receive FDA Clearance for Radiofrequency Ablation of Thyroid Nodules in the United States

Markets PR Newswire By PR Newswire 30 Jun 2026 12:00 1 min read
STARMED Becomes First Company to Receive FDA Clearance for Radiofrequency Ablation of Thyroid Nodules in the United States

Twenty-four years of clinical innovation. 300+ clinical studies. One historic first. LOS ANGELES, June 30, 2026 /PRNewswire/ -- STARMED America today announced FDA 510(k) clearance for the first RFA device in U.S. history indicated specifically for the ablation of thyroid nodules, making...

Twenty-four years of clinical innovation. 300+ clinical studies. One historic first. LOS ANGELES, June 30, 2026 /PRNewswire/ -- STARMED America today announced FDA 510(k) clearance for the first RFA device in U.S. history indicated specifically for the ablation of thyroid nodules, making...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.